Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Mayo Clinic proceedings - 1 Aug 2018

Ravindran Aishwarya, Fervenza Fernando C, Smith Richard J H, De Vriese An S, Sethi Sanjeev

Abstract excerpt

OBJECTIVE: To describe the clinicopathological features, complement abnormalities, triggers, treatment, and outcomes of C3 glomerulopathy. PATIENTS AND METHODS: A total of 114 patients with C3 glomerulopathy seen at Mayo Clinic from January 1, 2007, through December 31, 2016, were evaluated in this study. RESULTS: The mean age at diagnosis for the entire cohort was 40.4±22.3 years, with a median serum creatinine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Complement C3
Share to Complement System Proteins
Share to Glomerulonephritis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hematuria

Share to Infections

Share to Minnesota

Share to Paraproteinemias

Share to Proteinuria

Source

Open in PubMed Open full text

Identifiers

PMID: 30077216
DOI: 10.1016/j.mayocp.2018.05.019
PMCID: PMC6312642

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.PMID 30077216Read ↗

C3 Glomerulopathy: A Current Perspective in an Evolving LandscapeSemantic proximity Read ↗

C3 glomerulonephritis: clinicopathological findings, complement abnormalities, glomerular proteomic profile, treatment, and follow-up.Semantic proximity Read ↗

Acquired and genetic determinants of disease phenotype and therapeutic strategies in C3 glomerulopathy and immunoglobulin-associated MPGNSemantic proximity Read ↗

C3 glomerulopathy: what's in a name?Semantic proximity Read ↗

Complement inhibition in C3 glomerulopathy.Semantic proximity Read ↗

Reclassification of membranoproliferative glomerulonephritis: Identification of a new GN: C3GNSemantic proximity Read ↗

Defining the Complement Biomarker Profile of C3 GlomerulopathySemantic proximity Read ↗

Defining Nephritic Factors as Diverse Drivers of Systemic Complement Dysregulation in C3 GlomerulopathySemantic proximity Read ↗

C3 Glomerulopathy: A Review with Emphasis on Ultrastructural FeaturesSemantic proximity Read ↗

Membranoproliferative glomerulonephritis: no longer the same disease and may need very different treatmentSemantic proximity Read ↗

Pathogenesis of the C3 glomerulopathies and reclassification of MPGNSemantic proximity Read ↗

C3 glomerulopathy: a kidney disease mediated by alternative pathway deregulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.